Fund moves
9.9%Stake
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
SXTC · NASDAQ · Pharmaceutical Preparations · Foreign private issuer
China Sxt Pharmaceuticals (SXTC) · oqro.io/stocks/SXTC · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
No open-market purchase by an insider of China Sxt Pharmaceuticals is on record in SEC filings since 2006.
No open-market sale by an insider of China Sxt Pharmaceuticals (SXTC) was filed with the SEC in the last 90 days.
No trade in China Sxt Pharmaceuticals (SXTC) was disclosed by a member of Congress in the last 12 months.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
$2.65+0.055 (+2.12%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
−100.0% (−$1,613,997.36) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
No disclosed open-market insider trades, politician trades or fund 13F changes in this period.
Adjusted close went from $1,614,000.00 on Nov 20, 2025 to $2.65 on Nov 20, 2026 (−100.0%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in Taizhou. Foreign private issuer: reports on Form 20-F or 40-F. Its directors and officers file insider-trading forms (Form 4) only since 18 March 2026.
Last 12 months
−100.0%
Market value
–
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 28K shares sold short, −96.1% vs the previous count, 1.0 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Revenue, fiscal 2026
$1.14M
−34.6% vs the year before
Net income, fiscal 2026
−$6.21M
A loss for the year
Shares outstanding
958K
As of Mar 31, 2026
Reverse split 1-for-100 took effect Oct 26, 2026. Calendar
Fund moves
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Funds and stakes
Contracts, lobbying and filings
Company reports, price and press
Things to keep in mind
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Fiscal year Apr 1, 2025 to Mar 31, 2026, from the annual report filed Jul 1, 2026. Read the filing
−25% on the year before ($1.44M)
−81% on the year before ($258K)
−82% on the year before ($40K)
−99% on the year before ($4.3K)
The company also reports Revenues generated from third parties ($1.14M), which group lines above and are not added again.
Every annual report has a section where the company's managers explain the year's results (Item 5, Operating and financial review). In this report it runs to about 5,000 words.
We are an offshore holding company incorporated in British Virgin Islands and we conduct all of our business through our subsidiaries and the consolidated variable interest entity, Taizhou Suxuantang, in China. Neither we nor our subsidiaries own any share in Taizhou Suxuantang. Instead, WFOE, Taizhou Suxuantang and its shareholders entered into a series of contractual arrangements, also known as VIE Agreements, pursuant to which, we are regarded as the primary beneficiary of Taizhou Suxuantang for accounting purpose, and, therefore, we are able to consolidate the financial results of Taizhou Suxuantang in our consolidated financial statements in accordance with U.S. GAAP.
Source: SEC EDGAR, Form 20-F filed Jul 1, 2026. Revenue lines are the figures the company tags in its filing; OQRO shows a split only when its lines add up to the reported total revenue. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
And 13 more headings in the filing.
Fails to deliver: 15.6M shares (about $1.25M) were not delivered on time for settlement on Oct 14, 2026. SEC fails-to-deliver data.
Fails to deliver have many causes, including processing delays, and are often resolved within days.
Off-exchange trading: about 124.1 million shares a week traded away from the exchanges over the latest 4 published weeks, 8.9 million of them on ATS. Weeks of Sep 21 to Oct 16, 2026.
Largest ATS: BOATS (53.2%), LEVEL ATS (7.9%), INTELLIGENT CROSS LLC (7.0%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others.
Latest annual report filed Jul 1, 2026, compared with the one filed Jul 31, 2025. Read the filing
Source: SEC EDGAR, Form 20-F filed Jul 1, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.